Jinbo Bio has reported higher revenue for both the first quarter of 2026 and full-year 2025, with its beauty business gaining momentum alongside its core recombinant collagen operations. The company recorded first-quarter 2026 revenue of RMB 375 million, or about $54 million, up 2.43% year on year. Net profit attributable to shareholders fell 16.66% to RMB 140 million, or about $20 million.
Annual Revenue Rises While Profit Declines
For full year 2025, Jinbo Bio posted revenue of RMB 1.595 billion, or about $230 million, up 10.57% year on year. Net profit attributable to shareholders fell 10.95% to RMB 652 million, or about $94 million, according to the same source.
The figures point to a more mixed phase for one of China’s best-known recombinant collagen companies. Sales are still rising, but earnings are under pressure as growth slows and costs continue to move higher.
Costs Continue to Climb
Jinbo Bio’s first-quarter research and development spending rose 18.08% year on year to RMB 22.47 million, or about $3.2 million. Selling expenses also increased 12.42% to RMB 87.89 million, or about $12.7 million.
For Dewsia readers, the significance is broader than one earnings update. Recombinant collagen remains an active beauty growth area in China, but Jinbo Bio’s latest results suggest that scale and category expansion are no longer translating into the same level of profit growth as before.
